High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial

Introduction: Patients with life-threatening advanced non-small cell lung cancer (NSCLC) who harbor an exon 20 deletion and/or insertion mutation (EGFRex20 + ) have limited effective treatment options. The high dose 3rd generation tyrosine kinase inhibitor (TKI) osimertinib shows promising in vitro...

Full description

Bibliographic Details
Main Authors: de Langen, A.J (Author), Dingemans, A.-M.C (Author), Hashemi, S.M.S (Author), Hendriks, L.E.L (Author), Hiddinga, B.I (Author), Hijmering Kappelle, L.B.M (Author), Hiltermann, T.J.N (Author), ter Elst, A. (Author), van den Heuvel, M.M (Author), van der Leest, C. (Author), van der Wekken, A.J (Author), van Veggel, B. (Author), Zwierenga, F. (Author)
Format: Article
Language:English
Published: Elsevier Ireland Ltd 2022
Subjects:
Epidermal growth factor receptor
Exon 20 mutation
Non-small cell lung cancer
Osimertinib
Tyrosine kinase inhibitors
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items